Nuwacell Biotechnologies Co., Ltd. plans to industrially prepare iMSC (induced mesenchymal stem cells) through iPSC to solve existing problems and achieve the standardization and controllability of MSC therapy. iPSC has the characteristics of immortal proliferation. The “youngest” iMSC with the strongest proliferation function and full differentiation potential during embryonic or neonatal period can be prepared by increasing the initial number of iPSCs, without the need for excessive proliferation of MSCs to reach the required number of cells.

In addition, by optimizing the production process, we can produce iMSCs with differentiation tendency and use them for the treatment of specific diseases, for example, to prepare iMSCs that are easier to differentiate into cartilage for the treatment of rheumatoid arthritis.The industrialized and large-scale production of iMSCs under the GMP standard can be used for clinical treatment of different diseases and improve the efficiency and stability of cell therapy.